IVVD
Invivyd
Stock NASDAQ – Stock Market Prices, News & Analysis
Invivyd Inc, anciennement connue sous le nom de Adagio Therapeutics, est une entreprise biotechnologique dévelopant des solutions thérapeutiques pour la gestion des maladies infectieuses.
Invivyd
IVVD
Invivyd Inc, anciennement connue sous le nom de Adagio Therapeutics, est une entreprise biotechnologique dévelopant des solutions thérapeutiques pour la gestion des maladies infectieuses.
Price history of Invivyd
Price history of Invivyd
Performance & Momentum
Invivyd Reports Strong Q4 Growth, Launches COVID Antibody Phase 3
Invivyd announced preliminary product revenue of $17.2M for Q4 2025, up 25% year-over-year and 31% from the prior quarter, driven by its drug PEMGARDA. The company also initiated Phase 3 trials for VYD2311, an alternative COVID antibody to vaccines, with results expected by mid-2026. This trial benefits from Fast Track designation. Coupled with a strong $227M cash position, these clinical and financial strengths boost outlooks and have resulted in positive analyst consensus, targeting $10 per share.
Strategic Analysis
Invivyd • 2026
Invivyd Inc positions itself in biotechnology by developing innovative therapeutic solutions for infectious diseases, a sector with significant global health stakes. Its model is based on advanced research and the creation of targeted treatments, which allows it to differentiate itself in a competitive and constantly evolving market.
Strengths
- Strong recent growth highlighting a resurgence of interest and positive momentum for the stock
- Advanced technical expertise in a critical and growing therapeutic field
- Strategic positioning in infectious diseases, an essential segment of public health
Weaknesses
- Significant historical volatility, particularly over the medium and long term
- Lack of recent significant news that could support valuation
Momentum
The momentum is currently very favorable, reflecting a growing interest from investors and a marked upward trend. This calls for strategic vigilance to capitalize on the rising phase while remaining cautious of the inherent volatility in the biotechnology sector.
Similar stocks to Invivyd
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
